SMRT compounds abrogate cellular phenotypes of ataxia telangiectasia in neural derivatives of patient-specific hiPSCs.
about
Utility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on Childhood Neurological DisordersInduced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous SystemAtaxia telangiectasia derived iPS cells show preserved x-ray sensitivity and decreased chromosomal instabilityStem cells: the pursuit of genomic stability.A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene.Stem cells on the brain: modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells.Probing disorders of the nervous system using reprogramming approaches.Spontaneous ATM Gene Reversion in A-T iPSC to Produce an Isogenic Cell Line.Induced pluripotent stem cells from patients with focal cortical dysplasia and refractory epilepsy.Application of biomaterials to advance induced pluripotent stem cell research and therapy.Personalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.Pluripotent stem cells in disease modelling and drug discovery.hiPSC Disease Modeling of Rare Hereditary Cerebellar Ataxias.Lentiviral Reprogramming of A-T Patient Fibroblasts to Induced Pluripotent Stem Cells.Influence of ATM-Mediated DNA Damage Response on Genomic Variation in Human Induced Pluripotent Stem Cells.Nijmegen Breakage Syndrome fibroblasts and iPSCs: cellular models for uncovering disease-associated signaling pathways and establishing a screening platform for anti-oxidantsATM deficiency promotes progression of CRPC by enhancing Warburg effect
P2860
Q28080219-3CF86D3F-617B-47DB-A602-5248BC117D39Q28082668-A4ADB728-EBFC-486E-A36B-79B1CB039696Q33813801-B26E2624-2149-4698-8F34-108DED28D5ACQ34685564-C0838C47-22E2-444A-96E4-9EF1027A30D6Q34775214-E973DF44-6D8F-4512-813B-C3BEB36C8F3DQ34845881-FCD25492-2089-4032-827A-515111452D4EQ35761135-79A76901-8CD8-4BFE-83BE-3636A2025303Q36379473-7C3C8B41-3C48-4E8D-97B5-38887F5C7361Q37720208-5486EABC-42C8-4A9B-B490-4CFF8FD8D197Q38376035-3016D273-6F47-4ACE-AC33-0A701D290465Q38608688-E1A58316-499B-4E1D-B976-041E25EFCE27Q38714328-35B21B2A-F526-4127-9EC8-84F3C851F93EQ39172573-CEAA2A50-2EF1-471C-9866-E7227F7C5BE7Q40212979-742C3629-9F6E-427E-96D7-E01261A7039EQ40911800-5E0B92EB-E27D-4807-B8EF-454436BF5A75Q41308639-96A02F11-745C-4D01-826D-1FCC9B3CC847Q58542898-00A59CEB-FB89-44A8-B237-115A5445AC32
P2860
SMRT compounds abrogate cellular phenotypes of ataxia telangiectasia in neural derivatives of patient-specific hiPSCs.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
SMRT compounds abrogate cellul ...... es of patient-specific hiPSCs.
@ast
SMRT compounds abrogate cellul ...... es of patient-specific hiPSCs.
@en
SMRT compounds abrogate cellul ...... es of patient-specific hiPSCs.
@nl
type
label
SMRT compounds abrogate cellul ...... es of patient-specific hiPSCs.
@ast
SMRT compounds abrogate cellul ...... es of patient-specific hiPSCs.
@en
SMRT compounds abrogate cellul ...... es of patient-specific hiPSCs.
@nl
prefLabel
SMRT compounds abrogate cellul ...... es of patient-specific hiPSCs.
@ast
SMRT compounds abrogate cellul ...... es of patient-specific hiPSCs.
@en
SMRT compounds abrogate cellul ...... es of patient-specific hiPSCs.
@nl
P2093
P2860
P356
P1476
SMRT compounds abrogate cellul ...... es of patient-specific hiPSCs.
@en
P2093
Hailiang Hu
Kotoka Nakamura
Mandana Amiri
Nathan T Martin
Peiyee Lee
Richard A Gatti
Soheila Azghadi
Susan Perlman
Uri Ben-David
William E Lowry
P2860
P2888
P356
10.1038/NCOMMS2824
P407
P577
2013-01-01T00:00:00Z
P5875
P6179
1029072116